Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5990+0.0422 (+7.58%)
At close: 04:00PM EDT
0.6000 +0.00 (+0.17%)
After hours: 06:22PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4898
Open0.5000
Bid0.5300 x 800
Ask0.6000 x 3100
Day's Range0.5601 - 0.6000
52 Week Range0.3800 - 1.3400
Volume76,195
Avg. Volume141,450
Market Cap25.681M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.3630
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines." The allowed claims are directed to unique, proprietary compositions and me

  • Zacks Small Cap Research

    SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update SGX302 for Psoriasis Soligenix, Inc. (NASDAQ:SNGX) will be developing synthetic hypericin (the active ingredient in HyBryte) as part of a photodynamic therapy in mild-to-moderate psoriasis patients under the research name SGX302. Psoriasis is a common, chronic, noncontagious, multisystem inflammatory condition that

  • PR Newswire

    Soligenix to Present at the H.C. Wainwright Global Investment Conference

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming H.C. Wainwright Global Investment Conference. The conference will be held May 23 through 26, 2022 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Tue

Advertisement
Advertisement